PMV Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• PMV Pharmaceuticals Inc PMVP.OQ reported a quarterly adjusted loss of 41 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -2 cents. The mean expectation of four analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -40 cents to -37 cents per share.

• Reported revenue was zero​; analysts expected zero.

• PMV Pharmaceuticals Inc's reported EPS for the quarter was a loss of 41 cents​.

• The company reported a quarterly loss of $21.21 million.

• PMV Pharmaceuticals Inc shares had risen by 43.4% this quarter and gained 0.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for PMV Pharmaceuticals Inc is $6.00, about 74.7% above its last closing price of $1.52

This summary was machine generated from LSEG data August 7 at 05:44 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)